Nurix Therapeutics, Inc. (NRIX) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$17.16

From 52W high−41.45%

Volume14.79M

Market cap$1.78B

P/E (TTM)6.5x

P/S (TTM)2.5x

Div yield—

Key dataNov 4, 2026

Open

$17.16

From 52W high

−41.45%

Volume

14.79M

Market cap

$1.78B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

2.5x

P/E (TTM)

6.5x

RSI (14)

20.5

MomentumView details →

1D Return

−36.99%

YTD Return

−19.64%

SummaryUpdated Aug 1, 2026

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a biopharmaceutical company founded in 2009 and headquartered in San Francisco, California. The company went public in July 2020, raising capital to advance its innovative approach to drug discovery and development. Nurix focuses on developing small molecule therapies that leverage targeted protein degradation, a cutting-edge approach in biotechnology that aims to treat cancer and immune disorders by selectively destroying disease-causing proteins within cells.

Ask drillr about Nurix Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

6.5x

EV/EBITDA

2.5x

EV/Sales

1.1x

P/S (TTM)

2.5x

P/B (TTM)

1.8x

ProfitabilityView details →

Gross Margin

86.50%

Net Margin

42.01%

EBITDA Margin

45.96%

ROE (TTM)

30.45%

ROA (TTM)

24.67%

Asset Turnover

0.81x

GrowthView details →

Revenue YoY

+738.76%

EPS YoY

+184.51%

FCF YoY

+253.22%

Revenue CAGR 3Y

+29.55%

EPS CAGR 3Y

−5.90%

EBITDA YoY

+236.45%

MomentumView details →

1D Return

−36.99%

YTD Return

−19.64%

1Y Return

+22.35%

RSI (14)

20.5

vs 50D SMA

−38.32%

vs 200D SMA

−24.64%

Capital & dividendView details →

Debt/Equity

0.07x

Current Ratio

8.44x

Quick Ratio

8.44x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$4.73

EPS Surprise

887.14%

Beats (12Q)

5/12

Next Q EPS Est

−$0.41

Avg Surprise (4Q)

218.65%

Rev Surprise

2664.31%

Financials snapshotView financials →

Revenue (TTM)

701.94M

Net Income (TTM)

294.88M

Op. CF (TTM)

379.31M

Next earningsFeb 17, 2027 →

Latest newsMore news →

Nurix Therapeutics reported quarterly earnings of $4.73 per share, compared with a loss of $1.03 per share a year earlier.23d ago

Nurix Therapeutics, Inc. dosed the first patient in the Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed or refractory CLL/SLL.23d ago

Similar companies

Precigen, Inc.PGEN Stoke Therapeutics, Inc.STOK Braveheart Bio, Inc.BRVE Antengene Corporation Limited06996.HK Absci CorporationABSI AIM Vaccine Co., Ltd.06660.HK Find similar companies →

Latest newsMore news →

Nurix Therapeutics reported quarterly earnings of $4.73 per share, compared with a loss of $1.03 per share a year earlier.23d ago Nurix Therapeutics, Inc. dosed the first patient in the Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed or refractory CLL/SLL.23d ago